Two COVID-19 vaccine products for young children are nearing the final stages of the Emergency Use Authorization (EUA) process. Pfizer-BioNTech is submitting data on a THREE-dose primary series for a vaccine for children ages six months through FOUR years of age (6m–4y). Moderna is submitting data on a TWO-dose primary series for children ages six months through FIVE years of age (6m–5 y). The authorization is a multi-step clinical and regulatory process, and no vaccine can be administered until the final recommendation is issued by the CDC Director, Dr. Walensky. In preparation, this guidance includes details about BOTH products.